In patients with pancreatic ductal adenocarcinoma (PDAC), germline CDKN2A VUSs affecting p16INK4a, most often rare missense variants, are found in up to 4.3% of patients (Chaffee et al., 2018; Kimura et al., 2021; McWilliams et al., 2018; Roberts et al., 2016; Shindo et al., 2017; Zhen et al., 2015). Here, CDKN2A is linked to pancreatic ductal adenocarcinoma.